Island -
islandi -
LYFJASTOFNUN (Icelandic Medicines Agency)
vagidonna leggangatafla 10 míkróg
sandoz a/s* - estradiol - leggangatafla - 10 míkróg
Island -
islandi -
LYFJASTOFNUN (Icelandic Medicines Agency)
vagifem leggangatafla 10 míkróg
novo nordisk a/s* - estradiolum inn - leggangatafla - 10 míkróg
Island -
islandi -
LYFJASTOFNUN (Icelandic Medicines Agency)
zoladex vefjalyf 10,8 mg
astrazeneca ab - goserelinum acetat - vefjalyf - 10,8 mg
Island -
islandi -
LYFJASTOFNUN (Icelandic Medicines Agency)
rewellfem leggangatafla 10 míkróg
gedeon richter plc.* - estradiolum inn - leggangatafla - 10 míkróg
Euroopa Liit -
islandi -
EMA (European Medicines Agency)
elzonris
stemline therapeutics b.v. - tagraxofusp - lymphoma - Æxlishemjandi lyf - elzonris is indicated as monotherapy for the first-line treatment of adult patients with blastic plasmacytoid dendritic cell neoplasm (bpdcn).
Euroopa Liit -
islandi -
EMA (European Medicines Agency)
kimmtrak
immunocore ireland limited - tebentafusp - uveal neoplasms - Æxlishemjandi lyf - kimmtrak is indicated as monotherapy for the treatment of human leukocyte antigen (hla)-a*02:01-positive adult patients with unresectable or metastatic uveal melanoma.
Island -
islandi -
LYFJASTOFNUN (Icelandic Medicines Agency)
chanazine 10%, vet. stungulyf, lausn 10 %
chanelle pharmaceuticals manufacturing ltd* - xylazinum inn - stungulyf, lausn - 10 %
Island -
islandi -
LYFJASTOFNUN (Icelandic Medicines Agency)
zerofen 10% vet. mixtúra, dreifa 10 %
chanelle pharmaceuticals manufacturing ltd* - fenbendazolum inn - mixtúra, dreifa - 10 %
Island -
islandi -
LYFJASTOFNUN (Icelandic Medicines Agency)
flutiform (affilia) innúðalyf, dreifa 250 míkróg/10 míkróg
mundipharma a/s - fluticasonum própíónat; formoterolum fúmarat - innúðalyf, dreifa - 250 míkróg/10 míkróg
Island -
islandi -
LYFJASTOFNUN (Icelandic Medicines Agency)
phosphoral mixtúra, lausn 24,4 g/10,8 g
casen recordati s.l. - dinatrii hydrogenophosphas; natrii dihydrogenophosphas - mixtúra, lausn - 24,4 g/10,8 g